Company intelligence / Profile preview
Pharmbio Korea Inc.
- Ownership
- Private
- Employees
- ~315
- Development stage
- Phase 3
Overview
Pharmbio Korea Inc. is an active South Korean pharmaceutical manufacturer founded in 1999 specializing mainly in urologic medicines but also gastroenterology and general surgery-related pharmaceuticals. It develops small molecules and synthetic peptides targeting conditions such as urinary stones, gallstones/cholelithiasis symptoms, dyspepsia related liver issues plus other indications like apnea of newborns and osteoporosis. The firm has multiple approved drugs alongside late-stage clinical candidates while maintaining global partnerships that support steady growth through innovation-driven pipelines focused on unmet medical needs.
- Therapeutic areas
- GastroenterologyPulmonologyEndocrinologyNephrology
- Modalities
- Small moleculesSynthetic peptides
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Pharmbio Korea Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmbio Korea Inc..